Sensitivity analysis of frequency of use of low-dose aspirin in total or categorised by diabetes or hypertension in the 120- and 180-day follow-up period of NHI 2000†
| Characteristic A 120-day period | Haemorrhage (n=121) | Ischaemia (n=669) | Adjusted net clinical risk (%)§¶ (95% CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Use of low-dose aspirin | Rate difference‡ | Use of low-dose aspirin | Rate difference‡ | ||||||
| <20% | ≥80% | Crude (%) | Adjusted (%)¶ | <20% | ≥80% | Crude (%) | Adjusted (%)¶ | ||
| n (%) | n (%) | ||||||||
| All patients | 24 (0.13) | 97 (0.45) | 0.32 | 0.35*** | 52 (0.28) | 617 (2.85) | −2.57 | −2.23*** | 2.58*** (2.32 to 2.85) |
| Diabetes | |||||||||
| No | 17 (0.11) | 61 (0.39) | 0.28 | 0.32*** | 44 (0.28) | 458 (2.93) | −2.65 | −2.28*** | 2.60*** (2.30 to 2.91) |
| Yes | 7 (0.26) | 36 (0.60) | 0.34 | 0.53*** | 8 (0.30) | 159 (2.63) | −2.33 | −2.11*** | 2.64*** (2.07 to 3.21) |
| Hypertension | |||||||||
| No | 14 (0.12) | 41 (0.46) | 0.34 | 0.39*** | 21 (0.17) | 287 (3.19) | −3.02 | −2.53*** | 2.92*** (2.50 to 3.34) |
| Yes | 10 (0.16) | 56 (0.44) | 0.28 | 0.34*** | 31 (0.49) | 330 (2.61) | −2.12 | −1.83*** | 2.17*** (1.78 to 2.56) |
| Characteristic A 180-day period | Haemorrhage (n=145) | Ischaemia (n=716) | Adjusted net clinical risk (%)§ ¶ (95% CI) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Use of low-dose aspirin | Rate difference‡ | Use of low-dose aspirin | Rate difference‡ | ||||||
| <20% | ≥80% | Crude (%) | Adjusted (%)¶ | <20% | ≥80% | Crude (%) | Adjusted (%)¶ | ||
| n (%) | n (%) | ||||||||
| All patients | 42 (0.15) | 103 (0.50) | 0.33 | 0.38*** | 93 (0.34) | 623 (3.00) | −2.6 | −2.21*** | 2.50*** (2.24 to 2.76) |
| Diabetes | |||||||||
| No | 33 (0.14) | 62 (0.41) | 0.27 | 0.31*** | 73 (0.31) | 462 (3.09) | −2.78 | −2.19*** | 2.50*** (2.20 to 2.81) |
| Yes | 9 (0.21) | 41 (0.71) | 0.50 | 0.68*** | 20 (0.46) | 161 (2.78) | −2.32 | −1.92*** | 2.60*** (2.01 to 3.19) |
| Hypertension | |||||||||
| No | 24 (0.14) | 43 (0.50) | 0.36 | 0.43*** | 34 (0.20) | 289 (3.38) | −3.18 | −2.45*** | 2.88*** (2.46 to 3.30) |
| Yes | 18 (0.17) | 60 (0.49) | 0.32 | 0.37*** | 59 (0.56) | 334 (2.74) | −2.18 | −1.74*** | 2.11*** (1.75 to 2.47) |
†Major event includes haemorrhage (gastrointestinal haemorrhage or haemorrhagic stroke) or ischaemia (ischaemic stroke or acute myocardial infarction).
‡Difference in rate of haemorrhage was calculated as (haemorrhage rateuse of low-dose aspirin ≥80%)−(haemorrhage rateuse of low-dose aspirin <20%); difference in rate of ischaemia was calculated as (ischaemia rateuse of low-dose aspirin <20%)−(ischaemia rateuse of low-dose aspirin ≥80%).
§Net clinical risk=[(haemorrhage rateuse of low-dose aspirin ≥80%)−(haemorrhage rate use of low-dose aspirin <20%)]−[(ischaemia rateuse of low-dose aspirin <20%)−(ischaemia rateuse of low-dose aspirin ≥80%)].
¶Adjusting all variables listed in table 1. For subgroup analyses, all variables, except the variable classified, listed in table 1 was adjusted. Bootstrapping analysis with 1000 time replications was conducted to compute differences in predicted adjusted rates and bootstrap SEs.
*p<0.05; **p<0.01; ***p<0.001.
NHI, National Health Insurance.